

PA- 457



Drug Class: Opportunistic Infection and Other Drugs

PA-457 is a type of medicine called a maturation inhibitor. It is the first drug in this class to be studied for the treatment of HIV. Maturation inhibitors work by blocking viral maturation, a late step in HIV development that is needed for the virus to become infectious.

HIV/AIDS-Related Uses

PA-457 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied on fast-track status in Phase II trials for the treatment of HIV-1 infection in treatment-naïve or treatment-experienced patients. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration

PA-457 should be taken by mouth.

Recommended Daily Dose

PA-457 has been studied at doses of 25 to 250 mg and is taken once daily.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, PA-457 may cause some unwanted effects. Only mild side effects, including diarrhea with other stomach problems, were seen during early trials. Further study is needed to identify possible side effects of PA-457.

Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

For information on clinical trials that involve PA-457, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box,

enter: PA-457 AND HIV Infections.

Manufacturer Information

PA-457
Panacos Pharmaceuticals, Inc.
Corporate Headquarters
134 Coolidge Avenue
Watertown, MA 02472
(617) 926-1551

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET